With a lack of substantive data and the fact that GH therapy is non-reimbursable in many countries after attainment of adult height, delegates suggested monitoring IGF-I levels, especially in patients with confirmed GHD at transition, evaluating gonadotropin levels, and watching for early signs of obesity development, increasing hypotonia, decreased QoL, and a low activity level. Here, GH1 is linked to obesity disorder.